ArticleBMC geriatrics2026
Hepcidin in hospitalized older medical patients: associations with inflammation, anemia, frailty, comorbidity, and renal function.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Associations of length of stay with sarcopenia parameters in geriatric patients: age and sex differences in the oldest old.Aging clinical and experimental research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnemia is highly prevalent among hospitalized older adults and is associated with increased morbidity and mortality. Hepcidin is a liver-derived hormone that reduces iron availability and contributes to anemia. As the key regulator of iron metabolism, hepcidin is hypothesized to promote anemia development through inflammation-mediated pathways. However, the role of hepcidin in different types of anemia among frail, acutely hospitalized older patients remains poorly understood. The present study aimed to investigate the relationship between circulating hepcidin levels and markers of inflammation, anemia, frailty, comorbidity, and kidney function in a cohort of acutely hospitalized older patients.
methodsData from 1,030 patients aged ≥ 65 years from the Copenhagen PROTECT study were analyzed. Plasma hepcidin and interleukin-6 (IL-6) were measured using immunoassays, while standard biochemical markers, including hemoglobin and C-reactive protein (CRP), were assessed by routine clinical platforms. Anemia was defined according to WHO criteria. Frailty and comorbidity were evaluated using the Clinical Frailty Scale and the age-adjusted Charlson Comorbidity Index (CCI), respectively. Kidney function was determined by estimated glomerular filtration rate (eGFR). Correlations were examined using Pearson or Spearman methods depending on distribution and post hoc analyses included subgroup comparisons stratified by frailty and CCI strata. In exploratory multivariable analyses, hemoglobin was associated with hepcidin, inflammation, renal function, frailty, and comorbidity.
resultsAnemia was present in 48% of patients, with 10% of these displaying moderate-to-severe anemia. Hepcidin levels were significantly lower in patients with severe anemia compared to non-anemic patients. Notably, no consistent correlation was found between hepcidin and hemoglobin overall. Median hepcidin was 60.1 ng/mL [IQR 21.8-126.2] and showed moderate positive correlations with CRP (r = 0.48) and IL-6 (r = 0.47) (both p < 0.001). Hepcidin levels were lower in frail patients and varied modestly across comorbidity strata.
conclusionsIn this cohort of acutely admitted older medical patients, hepcidin was moderately associated with inflammation and showed modest associations with frailty, comorbidity, and anemia severity. Although no overall correlation was found between hepcidin and hemoglobin, patients with more severe anemia showed lower hepcidin levels. These findings suggest that inflammation is the primary driver of hepcidin regulation in this population.
trial registrationThe study was approved by the Regional Ethics Committee of Copenhagen and Frederiksberg (H19039214) and the Danish Data Protection Agency (P2019239).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.